稀土氨基酸配合物与核酸的相互作用*

很多抗癌金属药物是以核酸为靶标。阐明小分子与核酸之间的相互作用对筛选具有高效选择性和低毒副作用的抗癌药物有重要意义。近年来，开发新型的具有对核酸序列特异性识别能力的抗癌药物己成为本领域的研究热点。稀土离子具有良好的磁学、光学、电学特性和配位能力，使稀土配合物成为新型药物试剂。然而，稀土离子在中性条件下易水解的特性极大地阻碍了稀土配合物对核酸分子识别的研究。近年来在近生理条件下合成的一系列镧系氨基酸配合物具有结构稳定、溶解性好等优点，解决了镧系离子易水解的问题。本文总结了目前关于镧系氨基酸配合物与核酸的相互作用及其序列选择性等方面的研究进展。

Interactions of Rare Earth-Amino Acid Complexes with Nucleic Acids

A number of metal-based anticancer drugs are designed to target nucleic acids. Therefore, the elucidation of their interactions with nucleic acids is important for rational design of new anticancer agents with high selectivity and low toxicity, which has been received much attention in this field. Lanthanide complexes have the potential to be therapeutic agents due to their unique magnetic, optical, electronic, and coordinate characteristics. However, lanthanide ions are easy to hydrolysis under physiological pH, which makes it difficult to study rare earth complexes nucleic acids selectivity. Recent studies have shown that natural amino acids can form stable complexes with rare earth ions under near physiological condition and the complexes have high solubility. This review summarizes the current progress in rare earth-amino acid complexes binding to nucleic acids and their selectivity. Contents
1 Introduction
2 Structural diversity of rare earth-amino acid complexes
3 Molecular recognition of DNA by rare earth-amino acid complexes
3.1 Molecular recognition between rare earth-amino acid complexes and single-stranded DNA
3.2 Molecular recognition between rare earth-amino acid complexes and duplex DNA
3.3 Molecular recognition between rare earth-amino acid complexes and quadruplex DNA
4 Prospects